دورية أكاديمية
أعرض في EDS

Unmasking hidden risks: The surprising link between PDE5 inhibitors and seizure susceptibility.

التفاصيل البيبلوغرافية
العنوان: Unmasking hidden risks: The surprising link between PDE5 inhibitors and seizure susceptibility.
المؤلفون: Silva ALMD; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Nascimento CP; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Azevedo JEC; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Vieira LR; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Hamoy AO; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Tiago ACDS; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Martins Rodrigues JC; Laboratory of Experimental Neuropathology, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., de Araujo DB; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Favacho Lopes DC; Laboratory of Experimental Neuropathology, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., de Mello VJ; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil., Hamoy M; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil.
المصدر: PloS one [PLoS One] 2023 Nov 30; Vol. 18 (11), pp. e0294754. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Phosphodiesterase 5 Inhibitors*/adverse effects , Seizures*, Animals ; Male ; Rats ; Anticonvulsants/adverse effects ; Diazepam ; Pentylenetetrazole/adverse effects ; Phenobarbital/adverse effects ; Rats, Wistar ; Sildenafil Citrate/adverse effects ; Tadalafil/adverse effects
مستخلص: Background: Phosphodiesterase 5 inhibitors (PDE5i) are the first line treatment for erectile dysfunction; however, several articles and case reports have shown central nervous system effects, that can cause seizures in susceptible patients. This study aims to describe the changes caused by the use of Sildenafil and Tadalafil through the analysis of abnormalities expressed in the electrocorticogram (ECoG) of rats and evaluate the seizure threshold response and treatment of seizures with anticonvulsants.
Materials and Methods: The study used 108 rats (Wistar). Before surgery for electrode placement in dura mater, the animals were randomly separated into 3 experiments for electrocorticogram analysis. Experiment 1: ECoG response to using PD5i (Sildenafil 20mg/kg and Tadalafil 2.6mg/kg p.o.). Experiment 2: ECoG response to the use of PD5i in association with Pentylenetetrazole (PTZ-30 mg/kg i.p.), a convulsive model. Experiment 3: ECoG response to anticonvulsant treatment (Phenytoin, Phenobarbital and Diazepam) of seizures induced by association IPDE5 + PTZ. All recordings were made thirty minutes after administration of the medication and analyzed for ten minutes, only once. We considered statistical significance level of *p<0.05, **p<0.01 and ***p < 0.001.
Results: After administration of Sildenafil and Tadalafil, there were increases in the power of recordings in the frequency bands in oscillations in alpha (p = 0.0920) and beta (p = 0.602) when compared to the control group (p<0.001). After the use of Sildenafil and Tadalafil associated with PTZ, greater potency was observed in the recordings during seizures (p<0.001), however, the Sildenafil group showed greater potency when compared to Tadalafil (p<0.05). Phenobarbital and Diazepam showed a better response in controlling discharges triggered by the association between proconvulsant drugs.
Conclusions: PDE5i altered the ECoG recordings in the rats' motor cortexes, demonstrating cerebral asynchrony and potentiating the action of PTZ. These findings demonstrate that PDE5i can lower the seizure threshold.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Silva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Horm Behav. 2020 Jun;122:104753. (PMID: 32302594)
Int Immunopharmacol. 2023 Mar;116:109772. (PMID: 36731152)
Prim Care Companion CNS Disord. 2018 Jan 18;20(1):. (PMID: 29360291)
Front Hum Neurosci. 2019 Jan 09;12:521. (PMID: 30687041)
Epilepsy Behav. 2016 Aug;61:6-13. (PMID: 27232376)
Handb Exp Pharmacol. 2011;(202):527-42. (PMID: 21290241)
Int J Neural Syst. 2020 Jan;30(1):1950018. (PMID: 31366249)
Epilepsy Behav. 2013 Sep;28(3):519-20. (PMID: 23896325)
West J Emerg Med. 2012 Nov;13(5):394-400. (PMID: 23359586)
Neuro Endocrinol Lett. 2018 Mar;39(1):75-82. (PMID: 29803211)
Pharmaceuticals (Basel). 2020 Mar 10;13(3):. (PMID: 32164340)
Neurosci Biobehav Rev. 2019 Dec;107:136-142. (PMID: 31518638)
Ann N Y Acad Sci. 2007 Feb;1097:156-67. (PMID: 17413018)
Biol Psychol. 2004 Oct;67(1-2):219-33. (PMID: 15130532)
Biol Psychiatry. 2006 Nov 15;60(10):1111-20. (PMID: 16806100)
Med Clin (Barc). 2021 Oct 8;157(7):356-357. (PMID: 33277021)
BMJ. 2002 Oct 19;325(7369):869. (PMID: 12386039)
Psychopharmacology (Berl). 2009 Jan;202(1-3):411-7. (PMID: 18716761)
J Neural Transm (Vienna). 2012 Aug;119(8):923-31. (PMID: 22315091)
Neural Plast. 2019 Jul 9;2019:2687150. (PMID: 31360161)
Toxicol Appl Pharmacol. 2018 Dec 1;360:193-200. (PMID: 30296455)
Curr Opin Neurobiol. 2017 Jun;44:222-227. (PMID: 28575720)
Arch Gen Psychiatry. 1983 Nov;40(11):1243-8. (PMID: 6639294)
Br J Pharmacol. 2018 Apr;175(7):987-993. (PMID: 29520785)
Psychiatry Res. 2006 Jun 15;142(2-3):107-28. (PMID: 16712954)
Psychopharmacology (Berl). 2019 Dec;236(12):3687-3693. (PMID: 31392357)
BMJ. 2006 Oct 14;333(7572):785. (PMID: 17038735)
Br J Pharmacol. 2018 Jul;175(13):2554-2565. (PMID: 29667180)
PLoS One. 2013;8(3):e60060. (PMID: 23555884)
Neurotox Res. 2018 Oct;34(3):333-346. (PMID: 29427285)
Gene. 1998 Aug 17;216(1):139-47. (PMID: 9714779)
Clin Neuropharmacol. 2008 Nov-Dec;31(6):353-62. (PMID: 19050413)
Hum Brain Mapp. 2009 Mar;30(3):734-48. (PMID: 18266217)
Brain Res Bull. 2019 Jul;149:60-74. (PMID: 31004733)
Pharmacol Rep. 2009 Sep-Oct;61(5):930-4. (PMID: 19904018)
Seizure. 2011 Jun;20(5):409-13. (PMID: 21377383)
Neurotoxicology. 2020 May;78:21-28. (PMID: 32035075)
Neuroscience. 2018 May 15;378:54-70. (PMID: 27241945)
J Cogn Neurosci. 2018 Jun;30(6):867-875. (PMID: 29488848)
Stroke. 1976 Jan-Feb;7(1):46-53. (PMID: 1258104)
Toxicol Lett. 2016 Aug 10;256:44-52. (PMID: 27220266)
Rev Neurol (Paris). 2006 May;162(5):651-2. (PMID: 16710134)
Int J Psychophysiol. 2016 May;103:12-21. (PMID: 25659527)
Eur J Pharmacol. 2019 Sep 5;858:172446. (PMID: 31202800)
Eur J Pharmacol. 2009 Sep 1;617(1-3):79-83. (PMID: 19595687)
Front Endocrinol (Lausanne). 2019 Sep 24;10:654. (PMID: 31616380)
Balkan Med J. 2016 Mar;33(2):204-11. (PMID: 27403391)
Antioxidants (Basel). 2020 Oct 22;9(11):. (PMID: 33105652)
Transl Neurosci. 2018 Sep 01;9:106-116. (PMID: 30191077)
Neuropsychopharmacology. 2016 Apr;41(5):1231-40. (PMID: 26329382)
Curr Pharm Des. 2006;12(27):3439-57. (PMID: 17017938)
Arch Gen Psychiatry. 1983 Jul;40(7):719-28. (PMID: 6860073)
Neuropharmacology. 2019 Dec 15;161:107446. (PMID: 30481526)
J Headache Pain. 2018 Jun 18;19(1):44. (PMID: 29916084)
Br J Pharmacol. 2006 Apr;147(8):935-43. (PMID: 16474413)
Physiol Rev. 2011 Apr;91(2):651-90. (PMID: 21527734)
J Appl Physiol (1985). 2009 Apr;106(4):1234-42. (PMID: 19179645)
Neuroimage. 2014 Dec;103:119-129. (PMID: 25219334)
Surv Ophthalmol. 1999 Sep-Oct;44(2):153-62. (PMID: 10541153)
J Sex Med. 2016 Apr;13(4):465-88. (PMID: 27045254)
Front Cell Neurosci. 2022 May 11;16:872743. (PMID: 35634465)
Neurol Res. 2009 Apr;31(3):313-5. (PMID: 19036180)
Biomed Pharmacother. 2018 Nov;107:1674-1681. (PMID: 30257385)
Ann Pharmacother. 2002 Jul-Aug;36(7-8):1129-34. (PMID: 12086542)
Neuropsychiatr Dis Treat. 2008 Apr;4(2):371-87. (PMID: 18728748)
Neurochem Int. 2015 Nov;90:20-7. (PMID: 26142570)
Acta Histochem. 2018 May;120(4):312-322. (PMID: 29526379)
Pharmacol Rep. 2010 Mar-Apr;62(2):383-91. (PMID: 20508294)
المشرفين على المادة: 0 (Anticonvulsants)
Q3JTX2Q7TU (Diazepam)
WM5Z385K7T (Pentylenetetrazole)
YQE403BP4D (Phenobarbital)
0 (Phosphodiesterase 5 Inhibitors)
BW9B0ZE037 (Sildenafil Citrate)
742SXX0ICT (Tadalafil)
تواريخ الأحداث: Date Created: 20231130 Date Completed: 20240102 Latest Revision: 20240102
رمز التحديث: 20240102
مُعرف محوري في PubMed: PMC10688920
DOI: 10.1371/journal.pone.0294754
PMID: 38033148
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0294754